• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconGilead Sciences

Gilead Sciences

Why an exec at biopharma giant Gilead Sciences prefers energy management over time management
C-Suite
Why an exec at biopharma giant Gilead Sciences prefers energy management over time management
By Ruth UmohApril 13, 2026
U.S. approves twice-a-year shot to prevent HIV but cuts to public health and foreign aid cloud its prospects
Health
U.S. approves twice-a-year shot to prevent HIV but cuts to public health and foreign aid cloud its prospects
By Lauran Neergaard and The Associated PressJune 19, 2025
In patient with long-term COVID-19, coronavirus mutated to resist antiviral Remdesivir
Health
In patient with long-term COVID-19, coronavirus mutated to resist antiviral Remdesivir
By Jason Gale and BloombergNovember 11, 2021
Brainstorm Health 2021-Healthcare Companies Collaboration-Adams-Harrison-Bourla-O'Day
Conferences
Can the pandemic-induced collaboration among health care companies have a real impact on inequality?
By Sheryl EstradaApril 29, 2021
Brainstorm Health 2021-Gilead-Daniel O'Day
Conferences
Gilead’s remdesivir is now used to treat half of hospitalized COVID patients
By Sy MukherjeeApril 28, 2021
Gilead shares jump on FDA approval of remdesivir
Health
Gilead shares jump on FDA approval of remdesivir
By Robert Langreth and BloombergOctober 23, 2020
Gilead remdesivir coronavirus FDA
Health
Gilead says remdesivir slashes coronavirus deaths. But it’s complicated
By Sy MukherjeeJuly 10, 2020
Gilead coronavirus treatment drug Remdesivir
Health
Gilead to charge thousands for coronavirus treatment drug that critics say should cost $1
By Robert Langreth and BloombergJune 29, 2020
The April stocks rally defied the odds. Here’s what’s driving markets
Newsletters
The April stocks rally defied the odds. Here’s what’s driving markets
By Bernhard WarnerApril 30, 2020
Big Pharma has the chance to come to the world’s rescue
Magazine
Big Pharma has the chance to come to the world’s rescue
By Sy MukherjeeApril 20, 2020
Gilead coronavirus drug effective in coronavirus patients: report
Health
Gilead stock surges on report of coronavirus drug patients ‘seeing rapid recoveries’
By Drew Armstrong and BloombergApril 16, 2020
Gilead coronavirus
Newsletters
Gilead made a remarkable request of the FDA in regard to its coronavirus drug
By Sy MukherjeeMarch 25, 2020
Anti-influenza Avigan from Japan's Fujifilm helped clear the virus from patients a week earlier than the HIV medicine and was associated with improved chest symptoms shown on CT scans.
Health
HIV pill fails while flu medication helps in early coronavirus drug trials
By Jason Gale and BloombergMarch 19, 2020
Gilead coronavirus trial
Newsletters
Can Gilead tame the coronavirus?
By Sy MukherjeeFebruary 27, 2020
Gilead remdesivir clinical trials
Health
Gilead’s coronavirus treatment is barreling its way into new clinical trials
By Sy MukherjeeFebruary 26, 2020
1
  • 1
  • 2
2
Most Popular
Big Tech
As Big Tech showers employees with perks to win the talent war, Nvidia built a nearly $5 trillion company by making people pay for their own lunchplaceholder alt text
By Marco Quiroz-GutierrezJuly 1, 2026
Success
Mark Zuckerberg feeds his cows macadamia nuts and beer to create the 'highest-quality beef in the world' on his $300 million estate in Hawaiiplaceholder alt text
By Sasha RogelbergJuly 2, 2026
Success
Today, Emily Blunt is worth $80 million thanks to her Hollywood career—but she actually wanted to be a UN Spanish translator on $80Kplaceholder alt text
By Orianna Rosa RoyleJuly 2, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.